Comparison of Two- Versus Three-antibiotic Therapy for Pulmonary Mycobacterium Avium Complex Disease (MAC2v3)
Mycobacterium Avium Complex, Nontuberculous Mycobacterium Infection
About this trial
This is an interventional treatment trial for Mycobacterium Avium Complex focused on measuring NTM, MAC, mycobacteria, nontuberculous mycobacteria, azithromycin, ethambutol, rifampin
Eligibility Criteria
Inclusion Criteria:
- Culture positive pulmonary MAC meeting ATS/IDSA disease criteria
- Age over 18 years
- Ability to provide informed consent
Exclusion Criteria:
- Fibrocavitary disease
- Planned surgery for MAC disease
- Patients who have cumulatively taken 6 weeks or more of multi-drug antimicrobial treatment for MAC
- Patients who are currently taking or have taken multi-drug antimicrobial treatment for NTM within the prior 30 days
- Diagnosis of Cystic fibrosis
- Diagnosis of HIV
- History of solid organ or hematologic transplant
- Significant drug-drug interaction not clinically manageable in the opinion of the investigator
- Contraindication to any component of the study treatment regimen
Sites / Locations
- Loma Linda University Medical CenterRecruiting
- University of California, San DiegoRecruiting
- University of California, San FranciscoRecruiting
- Stanford UniversityRecruiting
- National Jewish HealthRecruiting
- Yale University
- Georgetown University
- University of Miami
- Tampa VA Medical CenterRecruiting
- Emory UniversityRecruiting
- Kaiser Permanente HawaiiRecruiting
- University of IowaRecruiting
- University of Kansas
- Louisina State UniversityRecruiting
- Johns Hopkins UniversityRecruiting
- Mayo ClinicRecruiting
- Northwell HealthRecruiting
- New York UniversityRecruiting
- Columbia University Medical CenterRecruiting
- University of North CarolinaRecruiting
- Oregon Health & Science UniversityRecruiting
- Temple UniversityRecruiting
- Medical University of South CarolinaRecruiting
- University of Texas Health Science CenterRecruiting
- University of Washington
- Vancouver ClinicRecruiting
- University of Wisconsin School of Medicine and Public HealthRecruiting
- University Health NetworkRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
2-drug regimen
3-drug regimen
This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.
This arm is a 3 time per week (TIW) treatment regimen that includes azithromycin 500 mg po + ethambutol 25 mg/kg + rifampin 600 mg Treatment changes are at the discretion of the treating physician and patient. Where possible, changes in dosing or frequency that allow the patient to continue taking the assigned drugs during the 12 months study period are preferred.